Net Asset Value

RNS Number : 1545B

Port Erin Biopharma Investments Ltd

11 April 2012

 



Port Erin Biopharma Investments Limited

(the "Company")

Net Asset Value calculation for the second trading quarter to 31^st March 2012

Tom Winnifrith, Chief Investment Officer, commented: -

"The Net Asset Value calculation for the Company as at closing on 31^st March 2012 is 9.59 pence per share, an increase of 12.0% since the last valuation.

This is again a satisfactory result, reflecting both a cumulative profit since inception of £162,086 and also a growth in Net Assets of £338,007 since the last quarter's valuation. We have now invested the bulk of the cash, leaving £486,580 remaining for further opportunities.

The market performance of both Arrowhead Research, a nanomedicine company with developments in RNAi therapeutics and obesity control; and Plethora Solutions, specialising in products for the treatment and management of urological disorders, where Jim Mellon has joined the board, is particularly noteworthy. Both companies have recently reported positive progress which is very encouraging."

		Unaudited 15 September to  31 March 2012 £
Fixed Assets
	Investments	2,673,633
Current Assets
	Sundry Debtors	12,123
	Uninvested cash	486,580
Current Liabilities
	Creditors: amounts due	(9,250)
		3,163,086
Capital and Reserves
	Share Capital	33
	Share Premium	3,000,967
	Capital reserve - realised	0
	Capital reserve - unrealised	0
	Revenue reserve	162,086
		3,163,086
Shares in Issue		33,000,000
Net Asset Value per share		9.59 pence

Company	Valuation GBP	% of Portfolio
Arrowhead Research	£396,299.56	14.8%
Pfizer Inc.	£207,329.58	7.8%
Plethora Solutions	£190,356.47	7.1%
Novartis AG	£156,362.73	5.9%
Synergy Pharmaceuticals Inc.	£140,485.93	5.3%
Astellas Pharma Inc.	£133,810.51	5.0%
Abbott Laboratories	£110,794.87	4.1%
Merck & Co. Inc.	£91,043.15	3.4%
Onyx Pharmaceuticals	£86,093.81	3.2%
Nektar Therapeutics	£85,628.52	3.2%
H Lundebeck A/S	£72,500.31	2.7%
Immunocellular Therapeutics Ltd.	£68,445.90	2.6%
Celgene Corp.	£68,231.39	2.6%
Map Pharmaceuticals Inc.	£67,796.12	2.5%
Eli Lilly & Co.	£66,788.62	2.5%
Medivir AB-B	£65,701.06	2.5%
Shire plc	£64,320.20	2.4%
Rigel Pharmaceutical Inc.	£63,784.87	2.4%
Ampliphi Biosciences Corp.	£62,539.09	2.3%
Synergy Pharmaceuticals Inc.	£58,712.32	2.2%
Polymedix Inc.	£53,683.55	2.0%
Pharmathene Inc.	£51,829.27	1.9%
Medivation Inc.	£50,700.44	1.9%
Siga Technologies Inc.	£49,193.25	1.8%
Miraculins Inc.	£34,224.52	1.3%
Synta Pharmaceuticals Corp.	£31,774.86	1.2%
Spiritus Pharmaceuticals, LLC	£31,269.54	1.2%
Pacific Biosciences California Inc.	£28,026.89	1.1%
Biotime Inc.	£27,747.34	1.0%
Methylgene Inc.	£24,470.92	0.9%
Complete Genomics Inc.	£23,386.49	0.9%
Synergy warrants (publicly traded)	£10,300.81	0.4%
TOTAL INVESTMENTS	£2,673,632.89

ENDS  

For further information, please contact:

Port Erin Biopharma Investments Ltd	Libertas Capital Corporate Finance Limited	Rivington Street Corporate Finance Limited
The Company	Nomad	Broker
Tom Winnifrith [phone]	Sandy Jamieson [phone]	Jon Levinson [phone]

 

END

 

 

NAVLLFSSSAILLIF